Comparative Pharmacology
Head-to-head clinical analysis: EVEKEO versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEKEO versus EVEKEO ODT.
EVEKEO vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant